Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
Schmitz RSJM, Engelhardt EG, Gerritsma MA, Sondermeijer CMT, Verschuur E, Houtzager J, Griffioen R, Retèl V, Bijker N, Mann RM, van Duijnhoven F, Wesseling J, Bleiker EMA; Grand Challenge PRECISION Consortium. Schmitz RSJM, et al. Among authors: wesseling j. Eur J Cancer. 2023 Oct;192:113276. doi: 10.1016/j.ejca.2023.113276. Epub 2023 Aug 4. Eur J Cancer. 2023. PMID: 37657228 Free PMC article.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC. Bueno-de-Mesquita JM, et al. Among authors: wesseling j. Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Lancet Oncol. 2007. PMID: 18042430
Is DCIS breast cancer, and how do I treat it?
Bijker N, Donker M, Wesseling J, den Heeten GJ, Rutgers EJ. Bijker N, et al. Among authors: wesseling j. Curr Treat Options Oncol. 2013 Mar;14(1):75-87. doi: 10.1007/s11864-012-0217-1. Curr Treat Options Oncol. 2013. PMID: 23239193 Review.
Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.
Drukker CA, Nijenhuis MV, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Schmidt MK, Van't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC. Drukker CA, et al. Among authors: wesseling j. Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub 2014 Apr 24. Breast Cancer Res Treat. 2014. PMID: 24760482 Free PMC article.
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, Pijnappel RM, Bijker N, Rutgers EJ, Wesseling J. Elshof LE, et al. Among authors: wesseling j. Eur J Cancer. 2015 Aug;51(12):1497-510. doi: 10.1016/j.ejca.2015.05.008. Epub 2015 May 26. Eur J Cancer. 2015. PMID: 26025767 Free article. Clinical Trial.
389 results